Neumora Therapeutics (NMRA) Liabilities and Shareholders Equity (2022 - 2026)

Neumora Therapeutics' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $153.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 40.07% year-over-year to $153.9 million; the TTM figure through Mar 2026 stood at $746.6 million (down 43.9% YoY), while the FY2025 annual figure was $191.0 million, down 39.73% from the prior year.
• Liabilities and Shareholders Equity was $153.9 million for Q1 2026 at Neumora Therapeutics, down from $191.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $544.7 million in Q3 2023 to a low of $153.9 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $332.9 million across 5 years, with a median of $334.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity climbed 16.41% in 2023, then slumped 49.56% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $426.2 million in 2022, then grew by 16.41% to $496.2 million in 2023, then slumped by 36.12% to $317.0 million in 2024, then slumped by 39.73% to $191.0 million in 2025, then slipped by 19.46% to $153.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $153.9 million (Q1 2026), $191.0 million (Q4 2025), and $177.8 million (Q3 2025), per Business Quant data.